Home » T2Bacteria Impact on Diagnostics & Clinical Outcomes in Sepsis and Bloodstream Infections
T2Bacteria Impact on Diagnostics & Clinical Outcomes in Sepsis and Bloodstream Infections
The T2Bacteria® Panel provides species-specific results, directly from whole blood within 3 to 5 hours of first blood draw, often before the second dose of empiric antibiotics are given. This enables clinicians to target therapy for patients suspected of sepsis, when every hour counts.
To read a summary of clinical literature evaluating the performance and clinical outcomes of the T2Bacteria Panel for the diagnosis of bloodstream infections, download our latest white paper.
Please enter your email address for instant access to the white paper.
T2 Biosystems, an emerging leader in the field of in vitro diagnostics, is dedicated to saving lives and reducing the cost of healthcare by empowering clinicians to effectively treat patients faster than ever before. T2 Biosystems is focused on addressing critical unmet needs in healthcare starting with sepsis, one of the deadliest and most expensive conditions in hospitals today.
The T2Dx Instrument, the T2Bacteria and T2Candida Panels have received marketing authorization from the U.S. Food and Drug Administration. All other T2 Biosystems products are considered investigational and for research use only.
T2 Biosystems®, T2MR®, T2Bacteria®, T2Candida®, and T2Dx® are registered trademarks of T2 Biosystems, Inc. “T2Biosystems” and the T2 Biosystems, Inc. logo design are registered trademarks or trademarks of T2Biosystems, Inc. All software and documentation is subject to T2 Biosystems, Inc. copyrights. All rights reserved. T2Direct Diagnostics™, T2HemoStat™, T2Plex™, T2Cauris™, T2Resistance™ and T2SARS-CoV-2™ are trademarks of T2 Biosystems, Inc.
A recent article in @NatureMicrobiol highlights the importance of tests like #T2Candida and how they may enable early diagnosis of fungal infections, which lead to "faster initiation of appropriate treatment and improved survival rates."